Home | Welcome to Contract Pharma   
Last Updated Wednesday, June 19 2013
Print RSS Feed

Breaking News

Related Searches:
Affymax, Takeda Get Phase II Boost for Hematide

May 12, 2008
Takeda Global R&D Center and Affymax achieved positive 12-month data from their ongoing Phase II trial evaluating the safety and tolerability of Hematide, an investigational drug in development for the treatment of anemia associated with chronic…  Read More »
Abilify Gets Expanded Label

May 9, 2008
Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. received approval from the FDA for updated labeling for Abilify as an adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with Bipol…  Read More »
Draxis Health 1Q08

May 9, 2008
Draxis Health 1Q Revenues: $19.2 million  (-9%) 1Q Loss: $2.4 million (earnings were $2.5 million in 1Q07) Comments: Contract manufacturing revenues were $12.6 million (-11%) due to lower revenues of Genzyme's Hectorol. Sterile products…  Read More »
Eurand 1Q08

May 9, 2008
Eurand 1Q Revenues: $24.9 million (+24%) 1Q Loss: $1.6 million (loss of $1.2 million in 1Q07) Comments: Product sales were $32.0 million (+17%). Royalties were $2.7 million (+103%). R&D expenses were $7.1 million (+21%). Revenues includ…  Read More »
Enzon To Spin Off Biotech Business

May 8, 2008
Enzon Pharmaceuticals, Inc. announced plans to spin off its biotechnology business into an independent company focusing on the development of cancer treatments. Enzon will fund the new company with $150 million, which is expected to provide two to th…  Read More »
Quintiles To Acquire Eidetics

May 8, 2008
Quintiles Transnational Corp. has signed an agreement to acquire Eidetics, a privately held consulting firm located in Boston. Eidetics provides research-based market insights and data analytics to support business decision making in drug development…  Read More »
Strattera FDA-Approved for ADHD Maintenance


May 8, 2008
Eli Lilly and Co. received approval from the FDA for Strattera for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approv…  Read More »
MedImmune

May 7, 2008
MedImmune it has enhanced its leadership team to guide the company's expanded product pipeline and core scientific research. Jacqueline Hall has been appointed global vice president, product development team leadership; Lorin Roskos, Ph.D. has been a…  Read More »
Financial Report: Hospira 1Q08

May 7, 2008
Hospira 1Q Revenues: $888.7 million (+14%) 1Q Earnings: $65.4 million (loss of $29.4 million 1Q07) Comments: In the Americas, pharmaceuticals revenues grew was 11% to $462.6 million. However, the "Other Pharmaceuticals" unit, which…  Read More »
Kendle

May 7, 2008
Patricia Williams has been appointed to the position of vice  president, commercial operations, Kendle. In this newly created  position, Ms. Williams will provide leadership for global contract  execution and negotiation with the…  Read More »
Financial Report: Kendle 1Q08

May 7, 2008
Kendle 1Q Revenues: $158.8 million (+20%) 1Q Earnings: $5.6 million (+33%) Comments: The company achieved record service revenues of $114.1   million and record new business awards of $180 million, both up 20%.   Total business a…  Read More »
Merck Cuts 1,200 U.S. Reps

May 6, 2008
Merck plans to reduce the size of its U.S. sales force by 15%, firing 1,200 reps. The move comes in the wake of slowing cholesterol drug sales as well as increased generic competition, according to the company.     "Merck is ta…  Read More »
Novartis Meningitis Vaccine Shows Response

May 6, 2008
New Phase III data for Novartis' Menveo show that the vaccine produced a greater immune response against meningococcal serogroups A, C, W-135 and Y in adolescents 11-18 years of age compared to Sanofi Pasteur's Menactra. Infection with any of these f…  Read More »
Goodwin Biotechnology Completes Expansion

May 6, 2008
Goodwin Biotechnology, Inc. (GBI) has completed the expansion of its cGMP manufacturing space, doubling its capacity. The expansion includes the addition of a 200L and 500L stirred tank bioreactor train to its hollow fiber and perfusion capabilities,…  Read More »
BMS To Sell ConvaTec Unit

May 5, 2008
Bristol-Myers Squibb is selling its therapy and surgical care unit, ConvaTec, to two private equity firms, Nordic Capital and Avista Capital Partners for $4.1 billion. The sale, expected to close in the third quarter, is part of the company's strateg…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: